These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

528 related items for PubMed ID: 21305266

  • 21. Analyzing the factors associated with efficacy among teriparatide treatment in postmenopausal women with osteoporosis.
    Kong M, Gao C, Luan X, Fan C, Hao M, Jin C, Zhao J, Li H, Zhao J, Luan J, Lin Y, Li Q.
    BMC Musculoskelet Disord; 2024 Feb 03; 25(1):109. PubMed ID: 38310278
    [Abstract] [Full Text] [Related]

  • 22. The efficacy and tolerability of risedronate on bone mineral density and bone turnover markers in osteoporotic Chinese women: a randomized placebo-controlled study.
    Leung JY, Ho AY, Ip TP, Lee G, Kung AW.
    Bone; 2005 Feb 03; 36(2):358-64. PubMed ID: 15780963
    [Abstract] [Full Text] [Related]

  • 23. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate.
    Miller PD, Delmas PD, Lindsay R, Watts NB, Luckey M, Adachi J, Saag K, Greenspan SL, Seeman E, Boonen S, Meeves S, Lang TF, Bilezikian JP, Open-label Study to Determine How Prior Therapy with Alendronate or Risedronate in Postmenopausal Women with Osteoporosis Influences the Clinical Effectiveness of Teriparatide Investigators.
    J Clin Endocrinol Metab; 2008 Oct 03; 93(10):3785-93. PubMed ID: 18682511
    [Abstract] [Full Text] [Related]

  • 24. The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures.
    Hadji P, Zanchetta JR, Russo L, Recknor CP, Saag KG, McKiernan FE, Silverman SL, Alam J, Burge RT, Krege JH, Lakshmanan MC, Masica DN, Mitlak BH, Stock JL.
    Osteoporos Int; 2012 Aug 03; 23(8):2141-50. PubMed ID: 22159672
    [Abstract] [Full Text] [Related]

  • 25. Effects of one year daily teriparatide treatment on trabecular bone material properties in postmenopausal osteoporotic women previously treated with alendronate or risedronate.
    Gamsjaeger S, Buchinger B, Zoehrer R, Phipps R, Klaushofer K, Paschalis EP.
    Bone; 2011 Dec 03; 49(6):1160-5. PubMed ID: 21893225
    [Abstract] [Full Text] [Related]

  • 26. Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study.
    Naylor KE, Jacques RM, Paggiosi M, Gossiel F, Peel NF, McCloskey EV, Walsh JS, Eastell R.
    Osteoporos Int; 2016 Jan 03; 27(1):21-31. PubMed ID: 25990354
    [Abstract] [Full Text] [Related]

  • 27. Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density.
    Muschitz C, Kocijan R, Fahrleitner-Pammer A, Lung S, Resch H.
    J Bone Miner Res; 2013 Jan 03; 28(1):196-205. PubMed ID: 22836585
    [Abstract] [Full Text] [Related]

  • 28. Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease.
    Palomba S, Orio F, Manguso F, Falbo A, Russo T, Tolino A, Tauchmanovà L, Colao A, Doldo P, Mastrantonio P, Zullo F.
    Osteoporos Int; 2005 Sep 03; 16(9):1141-9. PubMed ID: 15928801
    [Abstract] [Full Text] [Related]

  • 29. Profile of changes in bone turnover markers during once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis.
    Sugimoto T, Nakamura T, Nakamura Y, Isogai Y, Shiraki M.
    Osteoporos Int; 2014 Mar 03; 25(3):1173-80. PubMed ID: 24108429
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Effect of strontium ranelate on lumbar spine bone mineral density in women with established osteoporosis previously treated with teriparatide.
    Anastasilakis AD, Polyzos SA, Avramidis A, Papatheodorou A, Terpos E.
    Horm Metab Res; 2009 Jul 03; 41(7):559-62. PubMed ID: 19204890
    [Abstract] [Full Text] [Related]

  • 32. Effects of alendronate and risedronate on bone mineral density and bone turnover markers in late postmenopausal women with osteoporosis.
    Atmaca A, Gedik O.
    Adv Ther; 2006 Jul 03; 23(6):842-53. PubMed ID: 17276952
    [Abstract] [Full Text] [Related]

  • 33. Denosumab versus zoledronic acid in patients previously treated with zoledronic acid.
    Anastasilakis AD, Polyzos SA, Gkiomisi A, Saridakis ZG, Digkas D, Bisbinas I, Sakellariou GT, Papatheodorou A, Kokkoris P, Makras P.
    Osteoporos Int; 2015 Oct 03; 26(10):2521-7. PubMed ID: 25990355
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data.
    McClung MR, Zanchetta JR, Racewicz A, Roux C, Benhamou CL, Man Z, Eusebio RA, Beary JF, Burgio DE, Matzkin E, Boonen S, Delmas P.
    Osteoporos Int; 2013 Jan 03; 24(1):293-9. PubMed ID: 22752050
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Romosozumab in postmenopausal women with low bone mineral density.
    McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster JY, Zanchetta JR, Wasserman SM, Katz L, Maddox J, Yang YC, Libanati C, Bone HG.
    N Engl J Med; 2014 Jan 30; 370(5):412-20. PubMed ID: 24382002
    [Abstract] [Full Text] [Related]

  • 38. The combination therapy with alfacalcidol and risedronate improves the mechanical property in lumbar spine by affecting the material properties in an ovariectomized rat model of osteoporosis.
    Shiraishi A, Miyabe S, Nakano T, Umakoshi Y, Ito M, Mihara M.
    BMC Musculoskelet Disord; 2009 Jun 15; 10():66. PubMed ID: 19527501
    [Abstract] [Full Text] [Related]

  • 39. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.
    Leder BZ, O'Dea LS, Zanchetta JR, Kumar P, Banks K, McKay K, Lyttle CR, Hattersley G.
    J Clin Endocrinol Metab; 2015 Feb 15; 100(2):697-706. PubMed ID: 25393645
    [Abstract] [Full Text] [Related]

  • 40. Methylation of bone SOST, its mRNA, and serum sclerostin levels correlate strongly with fracture risk in postmenopausal women.
    Reppe S, Noer A, Grimholt RM, Halldórsson BV, Medina-Gomez C, Gautvik VT, Olstad OK, Berg JP, Datta H, Estrada K, Hofman A, Uitterlinden AG, Rivadeneira F, Lyle R, Collas P, Gautvik KM.
    J Bone Miner Res; 2015 Feb 15; 30(2):249-56. PubMed ID: 25155887
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 27.